The lack of increased antibody reactivity to a non-HERV antigen (IRF5) in NHL-UT patients compared to HCs supports the specificity of this response and argues against a generalised immune activation [41]. This evidence concerns the gene IRF5 and non-Hodgkin lymphoma.